Our mission at xCures is to help patients and oncologists utilize any and all resources to fight advanced cancer. As a technology platform, we offer information and decision support directly to patients and oncologists. We also connect them with third-party resources from some of the best ‘patient first’ organizations to expand treatment options and services.
xCures has joined Aetion in the launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative.
BioMed Valley Discoveries
BioMed Valley Discoveries partnered with xCures to offer expanded access to ulixertinib, an ERK1/2 inhibitor for patients with advanced solid tumors no longer responding to standard of care. Learn More
BioSpark partnered with xCures to rapidly expand the scope of real-world oncology data and help patients and their physicians understand the best treatment options
Cellworks partnered with xCures to advance predictive algorithms based on molecular systems biology and personalize oncology through multi-omic therapy biosimulation.
Cancer Commons partners with xCures to provide a highly customized and personal experience for advanced cancer patients in need of treatment options.
COLONTOWN collaborates with xCures to create a comprehensive precision medicine resource for COLONTOWN University.
Critical Path Institute
The Critical Path Institute partnered with xCures to quickly abstract and structure clinical data to support drug repurposing studies in rare cancers.
xCures partnered with CureMatch to leverage their proprietary curated knowledge base and help match patients to the best therapy options based on the unique molecular makeup of their tumor.
xCures’ partnership with CureScience serves to better identify specific patients and patient populations that may benefit from a particular test or treatment.
DIPG/DMG Research Funding Alliance
DDRFA partnered with xCures to streamline DMG & DIPG research and enhance patient care by centralizing the collection and analysis of anonymized DMG patient data.
xCures is a founding member of a historic alliance of close to a hundred life sciences and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
The EHE Foundation partnered with xCures to set up a research registry for patients with epithelioid hemangioendothelioma (EHE)
Endeavor partnered with xCures to help screen and enroll patients who might be eligible for their PTCH1 clinical trial
Faeth partnered with xCures to launch a medical food clinical trial for treatment of patients with recent pancreatic adenocarcinoma or advanced PDAC and evaluate tolerability and satisfaction with the diet
The FibroFighters Foundation is collaborating with xCures on an Observational Research Study to advance knowledge about FLHCC across the country. FLHCC is a rare cancer primarily affecting adolescents and young adults. Enroll Here
Fibrolamellar Cancer Foundation
The Fibrolamellar Cancer Foundation has partnered with xCures to drive fibrolamellar carcinoma (FLC) research and find treatment options for patients with FLC, a rare and often-fatal disease.
Genome Medical and xCures have joined forces to provide genetic counselors access to xCures’ care summaries for patients based on electronic medical records from across the healthcare ecosystem.
Institute of Systems Biology
The Institute of Systems Biology has partnered with xCures to develop innovative clinical trials to advance systems biology algorithms in glioblastoma and multiple myeloma.
mProbe partnered with xCures to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets.
The Musella Foundation partnered with xCures and Cancer Commons to ensure that brain cancer patients get fast access to promising treatment options
Novocure has partnered with xCures to better understand the links between quality of life and treatment decisions, disease characteristics, and other factors for patients diagnosed with glioblastoma.
Oblato partnered with xCures to offer OKN-007 through an expanded access program for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG)
Oncoceutics collaborated with xCures and Cancer Commons to implement an Expanded Access program for ONC201
PanCAN partnered with xCures to give their researchers and grantees access to xCures’ de-identified data to improve research, and help their patients find the right treatments.
Patient Record Scorecard
xCures is a supporter of the Ciitizen Patient Record Scorecard that shows how medical record providers comply with the HIPAA Right of Access based on patient requests.
xCures collaborates with POETIC, a non-profit organization that manages pediatric oncology early phase trials, to get children, adolescents, and young adults with cancer enrolled in expanded access programs of promising therapies. Learn More
Prognos Health and xCures partnered to enable access to real-world oncology datasets and use continuous learning from every patient’s journey to drive insights and improve outcomes
RenovoRx partnered with xCures to help eligible patients with locally advanced pancreatic cancer get access to the TIGeR-PaC Phase III clinical study.
SonALAsense partnered with xCures to set up a Natural History study for DIPG and DMG, accelerating DIGP/DMG research, and ending randomization in pediatric clinical trials.Message received!
We sent a confirmation to your email address and our team will follow up with you as soon as possible.
We had a technical issue and can not confirm the message was delivered.
Please contact us directly at email@example.com
Get in touch
Want to know more about xCures? Leave your email and we'll get back to you.
Get in touch
Want to know more about xCures? Leave your email and we’ll get back to you.